Trial Profile
UARK 98-026, Total therapy II - a phase III study for newly diagnosed multiple myeloma evaluating anti-angiogenesis with thalidomide and post-transplant consolidation chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2023
Price :
$35
*
At a glance
- Drugs Thalidomide (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Interferon alpha-2a; Interferon alpha-2b; Melphalan; Vincristine
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms TT-II
- 06 Jun 2023 Results assessing follow up of MM trials (TT1 (NCT00580372), TT2 (NCT00083551), TT3a (NCT00081939) and TT3b (NCT00572169)) and reporting to date with RSRs to assess for curability,resented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 24 Sep 2005 New trial record.